Yiteng Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yiteng Jin has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Ce Luo
Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
3 shared publications - Zexian Zeng
Peking University
3 shared publications - Deng Pan
Tsinghua-Peking Center for Life Sciences, Department of Basic Medical Sciences, Tsinghua University, Beijing, China
2 shared publications Chao Wang
Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China
1 shared publication- Di Feng
Global Computational Biology and Data Science Department, Boehringer Ingelheim, Ridgefield, Connecticut
1 shared publication Haorui Zhang
Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 15 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Arid3b suppresses CD8 + T cell infiltration and function in microsatellite-stable colorectal cancer via Runx3
Microsatellite-stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC) is characterized by a cold tumor microenvironment, with limited CD8⁺ T cell infiltration and poor responsiveness to immune checkpoint inhibitors (ICIs). Here, using an in vivo CRISPR/Cas9 screen in a CMT93 cell-derived murine tumor model, we identify Arid3b as a key negative regulator of CD8⁺ T cell infiltration and antitumor activity. Genetic ablation of Arid3b in CD8⁺ T cells significantly enhances their intratumoral accumulation and promotes robust tumor control. Mechanistically, Arid3b deficiency upregulates Runx3 , driving a tissue-resident memory-like phenotype and effector function. Notably, the benefits conferred by Arid3b deficiency are abrogated upon Runx3 deletion, indicating a RUNX3-dependent mechanism. Together, targeting ARID3B could offer a promising strategy to reshape the tumor microenvironment and sensitize MSS CRC to immunotherapy.
- 15 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessArid3b suppresses CD8 + T cell infiltration and function in microsatellite-stable colorectal cancer via Runx3
Microsatellite-stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC) is characterized by a cold tumor microenvironment, with limited CD8⁺ T cell infiltration and poor responsiveness to immune checkpoint inhibitors (ICIs). Here, using an in vivo CRISPR/Cas9 screen in a CMT93 cell-derived murine tumor model, we identify Arid3b as a key negative regulator of CD8⁺ T cell infiltration and antitumor activity. Genetic ablation of Arid3b in CD8⁺ T cells significantly enhances their intratumoral accumulation and promotes robust tumor control. Mechanistically, Arid3b deficiency upregulates Runx3 , driving a tissue-resident memory-like phenotype and effector function. Notably, the benefits conferred by Arid3b deficiency are abrogated upon Runx3 deletion, indicating a RUNX3-dependent mechanism. Together, targeting ARID3B could offer a promising strategy to reshape the tumor microenvironment and sensitize MSS CRC to immunotherapy.
- 20 August 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
Perturbation of calreticulin potentiates CD8+ T cell–mediated antitumor immunity
Effective immunotherapy relies on the presentation of tumor-derived neoantigens on the major histocompatibility complex class I (MHC-I) to activate CD8+ T cells. Deficiencies in this process are a key mechanism of immune evasion and resistance to checkpoint blockade. In this study, using an in vivo CRISPR-Cas9 screen, we unexpectedly found that inactivation of calreticulin (CALR), and other selected components of the peptide-loading complex (PLC), induced robust CD8+ T cell–mediated immune responses. We show that this effect is dependent on the expression of classical MHC-I on tumor cells. Mechanistically, loss of CALR reshaped the MHC-I peptide repertoire, favoring the presentation of low-affinity peptides in murine and human cell lines. Genetic or pharmacological inhibition of PDIA3, another PLC component, similarly induced antitumor effects. These findings reveal a previously unrecognized role of CALR and the PLC in regulating antitumor immunity and suggest that targeting this pathway could be a promising strategy to overcome immune resistance and improve the efficacy of cancer immunotherapies.
- 20 August 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
Perturbation of calreticulin potentiates CD8+ T cell–mediated antitumor immunity
Effective immunotherapy relies on the presentation of tumor-derived neoantigens on the major histocompatibility complex class I (MHC-I) to activate CD8+ T cells. Deficiencies in this process are a key mechanism of immune evasion and resistance to checkpoint blockade. In this study, using an in vivo CRISPR-Cas9 screen, we unexpectedly found that inactivation of calreticulin (CALR), and other selected components of the peptide-loading complex (PLC), induced robust CD8+ T cell–mediated immune responses. We show that this effect is dependent on the expression of classical MHC-I on tumor cells. Mechanistically, loss of CALR reshaped the MHC-I peptide repertoire, favoring the presentation of low-affinity peptides in murine and human cell lines. Genetic or pharmacological inhibition of PDIA3, another PLC component, similarly induced antitumor effects. These findings reveal a previously unrecognized role of CALR and the PLC in regulating antitumor immunity and suggest that targeting this pathway could be a promising strategy to overcome immune resistance and improve the efficacy of cancer immunotherapies.
- Open Access
- 7 August 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (8) , 1043
GRB7 Plays a Vital Role in Promoting the Progression and Mediating Immune Evasion of Ovarian Cancer
Background: Despite breakthroughs in treatment, ovarian cancer (OC) remains one of the most lethal gynecological malignancies, with an increasing age-standardized mortality rate. This underscores an urgent need for novel biomarkers and therapeutic targets. Although growth factor receptor-bound protein 7 (GRB7) is implicated in cell signaling and tumorigenesis, its expression pattern and clinical implications in OC remain poorly characterized. Methods: To systematically investigate GRB7’s expression in OC, our study utilized extensive datasets from TCGA, GTEx, CCLE, and GEO. The prognostic significance of GRB7 was evaluated by means of Kaplan–Meier and Cox regression analyses. Using a correlation analysis and gene set enrichment analysis, relationships between GRB7’s expression and gene networks, immune cell infiltration and immunotherapy response were investigated. In vitro experiments were conducted to confirm GRB7’s function in the biology of OC. Results: Compared to normal tissues, OC tissues exhibited a substantial upregulation of GRB7. Reduced overall survival, disease-specific survival, and disease-free interval were all connected with high GRB7 mRNA levels. The network study demonstrated that GRB7 is involved in pathways relevant to the course of OC and has a positive connection with several key driver genes. Notably, GRB7’s expression was linked to the infiltration of M2 macrophage and altered response to immunotherapy. Data from single-cell RNA sequencing data across multiple cancer types indicated GRB7’s predominant expression in malignant cells. Moreover, OC cells with GRB7 deletion showed decreased proliferation and migration, as well as increased susceptibility to T cell-mediated cytotoxicity. Conclusion: With respect to OC, our results validated GRB7 as a viable prognostic biomarker and a promising therapeutic target, providing information about its function in tumorigenesis and immune modulation. GRB7’s preferential expression in malignant cells highlights its significance in the biology of cancer and bolsters the possibility that it could be useful in enhancing the effectiveness of immunotherapy.
- 7 August 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (8) , 1043
Open AccessGRB7 Plays a Vital Role in Promoting the Progression and Mediating Immune Evasion of Ovarian Cancer
Background: Despite breakthroughs in treatment, ovarian cancer (OC) remains one of the most lethal gynecological malignancies, with an increasing age-standardized mortality rate. This underscores an urgent need for novel biomarkers and therapeutic targets. Although growth factor receptor-bound protein 7 (GRB7) is implicated in cell signaling and tumorigenesis, its expression pattern and clinical implications in OC remain poorly characterized. Methods: To systematically investigate GRB7’s expression in OC, our study utilized extensive datasets from TCGA, GTEx, CCLE, and GEO. The prognostic significance of GRB7 was evaluated by means of Kaplan–Meier and Cox regression analyses. Using a correlation analysis and gene set enrichment analysis, relationships between GRB7’s expression and gene networks, immune cell infiltration and immunotherapy response were investigated. In vitro experiments were conducted to confirm GRB7’s function in the biology of OC. Results: Compared to normal tissues, OC tissues exhibited a substantial upregulation of GRB7. Reduced overall survival, disease-specific survival, and disease-free interval were all connected with high GRB7 mRNA levels. The network study demonstrated that GRB7 is involved in pathways relevant to the course of OC and has a positive connection with several key driver genes. Notably, GRB7’s expression was linked to the infiltration of M2 macrophage and altered response to immunotherapy. Data from single-cell RNA sequencing data across multiple cancer types indicated GRB7’s predominant expression in malignant cells. Moreover, OC cells with GRB7 deletion showed decreased proliferation and migration, as well as increased susceptibility to T cell-mediated cytotoxicity. Conclusion: With respect to OC, our results validated GRB7 as a viable prognostic biomarker and a promising therapeutic target, providing information about its function in tumorigenesis and immune modulation. GRB7’s preferential expression in malignant cells highlights its significance in the biology of cancer and bolsters the possibility that it could be useful in enhancing the effectiveness of immunotherapy.
- Open Access
- 7 August 2023
- Published by American Physical Society (APS) in Physical Review Research
- Vol. 5 (3) , L032018
Diffusion enhancement in bacterial cytoplasm through an active random force
Experiments have found that diffusion in metabolically active cells is much faster than in dormant cells, especially for large particles. However, the mechanism of this size-dependent diffusion enhancement in living cells is still unclear. In this Letter, we approximate the net effect of metabolic processes as a white-noise active force and simulate a model system of bacterial cytoplasm with a highly polydisperse particle size distribution. We find that diffusion enhancement in active cells relative to dormant cells can be more substantial for large particles. Our simulations agree quantitatively with the experimental data of Escherichia coli, suggesting an autocorrelation function of the active force proportional to the cube of the particle radius. We demonstrate that such a white-noise active force is equivalent to an active force of about 0.57 pN with random orientation. Our work unveils an emergent simplicity of random processes inside living cells.
- 7 August 2023
- Published by American Physical Society (APS) in Physical Review Research
- Vol. 5 (3) , L032018
Open AccessDiffusion enhancement in bacterial cytoplasm through an active random force
Experiments have found that diffusion in metabolically active cells is much faster than in dormant cells, especially for large particles. However, the mechanism of this size-dependent diffusion enhancement in living cells is still unclear. In this Letter, we approximate the net effect of metabolic processes as a white-noise active force and simulate a model system of bacterial cytoplasm with a highly polydisperse particle size distribution. We find that diffusion enhancement in active cells relative to dormant cells can be more substantial for large particles. Our simulations agree quantitatively with the experimental data of Escherichia coli, suggesting an autocorrelation function of the active force proportional to the cube of the particle radius. We demonstrate that such a white-noise active force is equivalent to an active force of about 0.57 pN with random orientation. Our work unveils an emergent simplicity of random processes inside living cells.